Lasa Supergenerics Limited (BOM:540702)
7.20
+0.28 (4.05%)
At close: Aug 21, 2026
Lasa Supergenerics Revenue
Lasa Supergenerics had revenue of 13.25M INR in the quarter ending June 30, 2026, a decrease of -93.42%. This brings the company's revenue in the last twelve months to 65.20M, down -95.23% year-over-year. In the fiscal year ending March 31, 2026, Lasa Supergenerics had annual revenue of 253.41M, down -82.82%.
Revenue (ttm)
65.20M
Revenue Growth
-95.23%
P/S Ratio
5.53
Revenue / Employee
987.86K
Employees
66
Market Cap
360.73M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 253.41M | -1.22B | -82.82% |
| Mar 31, 2025 | 1.47B | 430.26M | 41.20% |
| Mar 31, 2024 | 1.04B | -259.96M | -19.93% |
| Mar 31, 2023 | 1.30B | -66.97M | -4.88% |
| Mar 31, 2022 | 1.37B | -652.53M | -32.24% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Supha Pharmachem | 5.27B |
| Kimia Biosciences | 1.12B |
| Tyche Industries | 500.33M |
| Vasundhara Rasayans | 347.79M |
| Crestchem | 338.33M |
| Link Pharma Chem | 283.85M |
| Krebs Biochemicals & Industries | 252.34M |
| Ishita Drugs and Industries | 124.05M |